ABL Bio Obtains Japanese Patent for 'B7-H3 Monoclonal Antibody'
[Asia Economy Reporter Chunhee Lee] ABL Bio announced on the 11th that it has completed the registration of a Japanese patent for its B7-H3 monoclonal antibody.
B7-H3 is a protein expressed in various types of cancer tissues, including non-small cell lung cancer and prostate cancer. It affects T cell activation and is gaining attention as a new anticancer target. To date, no anticancer drugs targeting B7-H3 have been approved. However, globally, companies such as Xencor and Daiichi Sankyo are developing B7-H3 targeted therapies.
This Japanese patent was filed internationally by ABL Bio on May 24, 2019. It includes details on the anticancer effects of the B7-H3 monoclonal antibody in animal models. ABL Bio is conducting research and development (R&D) on bispecific antibodies utilizing the B7-H3 antibody and plans to continue registering patents filed in Korea, China, the United States, Europe, and other regions.
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- Man in His 40s Who Kept Girlfriend's Body for a Year After Murder Sentenced to 30 Years in Prison Again on Appeal
- "If You Booked This Month, You Almost Lost Out... Why You Should Wait Until 'This Day' Before Paying for Flight Tickets"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Lee Sang-hoon, CEO of ABL Bio, stated, “We are striving to secure patents to protect our antibody technology rights in multiple countries overseas, targeting the global market,” and added, “We will continue to strengthen our global competitiveness by exploring new anticancer targets and diversifying our pipeline for innovative drug development.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
